| Virginia Catherine Jensen Peden, PLMFT | |
|
21516 Highway 36, Abita Springs, LA 70420-3906 | |
| (985) 273-3857 | |
| Not Available |
| Full Name | Virginia Catherine Jensen Peden |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 21516 Highway 36, Abita Springs, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558958397 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | PLM1398 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Virginia Catherine Jensen Peden, PLMFT 25134 Highway 190, Lacombe, LA 70445-4514 Ph: () - | Virginia Catherine Jensen Peden, PLMFT 21516 Highway 36, Abita Springs, LA 70420-3906 Ph: (985) 273-3857 |
News Archive
New technologies and tests, an ageing population, greater community expectations around healthcare – including those based on the easy availability of medical information and personal health records – are just some of the factors which will make the health workforce of 2025 look very different to the health workforce of today.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the initiation of PERSIST-AVR, the first international, prospective, post-market randomized multi-center trial evaluating the Perceval sutureless aortic valve compared to standard sutured bioprostheses in patients with aortic valve disease.
Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay's decision to sell its Pharmaceuticals Sector to Abbott. Girindus is a member of Solvay Organics, which is part of the Chemicals Division of the Solvay Group and is therefore completely separate from the Pharmaceuticals Division.
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
In 2010 malaria caused an estimated 665,000 deaths, mostly among African children. Now, chemists at Indiana University have developed a new synthesis for the world's most useful antimalarial drug, artemisinin, giving hope that fully synthetic artemisinin might help reduce the cost of the live-saving drug in the future.
› Verified 2 days ago